BM = Bone marrow; mPB = G-CSF mobilized peripheral blood; FB = fetal blood; CB = cord blood; PLA = placenta; AM amniotic membrane; CM = chorionic membrane; CV = chorionic villi; ENDO = endometrium; ATSVF = adipose tissue stromal vascular fraction, AT = adipose tissue; PMSC = pancreas mesenchymal stem cells; DPSC = dental pulp stem cells; a Detection by real time PCR.
graft-versus-host disease suppression. MSC were first isolated from bone marrow (BM). Multipotent MSC-like cells were also isolated from adipose tissue, dental pulp, cord blood (CB), placenta, and many other tissues. The broad field of sources from which MSC can be isolated and all the different potential applications render necessary an extensive characterization and quality control, especially as MSC isolated from different tissues do not represent a homogenous cell population. There still is no simple way to define MSC by a single marker or a simple set of markers. In this review, we will summarize published literature and our own experience on expression of surface markers of MSC from various sources and in various stages of differentiation and culture.
Characterization of Mesenchymal Stem Cells
The most common surface marker molecules used to describe native or expanded MSC are listed in 
Discrepancies in Surface Marker Expression Profiles
The differences in various surface marker expressions observed by different investigators might be due to several factors. 
Impact of MSC Source
Most obviously, the tissue from which MSC are derived may play an important role for surface marker expression. Markers like Oct-4, Nanog, Rex-1, SSEA-3, SSEA-4, Tra-1-60, and Tra-1-81 are expressed on MSC from human first-trimester fetal blood, liver, and BM but not in expanded MSC derived from adult BM [1] . Furthermore, CD271 was shown to be present on a small population of unprocessed BM cells yielding high potent MSC by ex vivo expansion, but to our knowledge no report exists on the successful isolation of CB-derived MSC by this method. Whether CD271 is expressed on expanded BM-derived MSC from adults, is still not quite clear. In a recent work, Soncini et al. [2] published the isolation and characterization of BM-, amnion membrane-, and chorionic membrane-derived MSC. The expression profile of MSC isolated from all tissues was comparable [2] . However, there were variations in the percentage of positive cells after 4 passages (plastic adherence method for isolation) expressing positive markers, mainly CD73, CD105, and CD166. BM-derived MSC showed higher percentages of CD73-expressing cells than amnion membrane-and chorionic membrane-derived MSC, whereas percentages of CD105-and CD166-positive cells were lower in amnion membrane-derived MSC only. CD271 was present on less than 1% of BM, about 15% of amnion, and about 20% of chorionic preparations. CD271 expression disappeared during in vitro expansion.
Impact of Donor Age
Age and sex of MSC donors may play an important role. There is no systematic report on differences in surface marker expression. The potential of differentiation has been described to be dependent on the age of MSC donors. CD45 and CD14 expression was quite high for BM-derived MSC preparations from older patients (15 and 13%) at passage 1, compared to pediatric donors (3.6 and 2.2%). In contrast, expression of CD45 and CD14 decreased in older donors, whereas a slight increase was observed in pediatric donors [3] . However, these high values in older patients might be due to limited donor number or experimental layout and analysis of only 200-500 cells in flow cytometry. Besides, it is not clear whether MSC were positive for CD45 and/or CD14 or whether CD45+ or The corresponding BM derived MCS-preparations had comparable passage numbers but were from different donors (A, C from UL-SARK03 passage 4; B and D from UL-IKT03 passage 5). Passage-dependent decrease and appearance of a second population of surface marker CD146 is demonstrated in E and F. The data were acquired from the same BM-derived MSC preparation (UL-SARK02) but from different passages (passage 2 for E, passage 10 for F). The choice of antibody clone and fluorochrome also might influence expression profiling (G-K). BM-derived MSC preparations from different donors (UL-SARK02 (G, J, K), UL-RKUCH01 (H), and UL-551#1 (I)) with comparable matched passage numbers (passage 2 (G), passage 5 (H), passage 6 (I), passage 10 (J), and passage 12 (K)) were stained with 2 different, commercially available antibodies to CD117. Antibodies were labeled with PE (G, H, J clone YN5.B8) or APC (I, K clone 104D2). MSC preparations were negative when stained with the PE-labeled antibody, but a subpopulation of positive cells could be detected when cells were stained with the APC-labeled antibody. Fluorescence intensities of 50,000-100,000 cells were acquired after applying a standard antibody-staining protocol for cell lines as previously described [86, 87] . Discrepancies in the data from this figure and from table 2 are discussed in the text.
CD14+ cells were accidentally co-cultured. No differentiation or functional assays were performed with isolated or expanded CD45+ or CD14+ cells alone. On the other hand, CD106 is up-regulated in MSC from pediatric donors, and a great variation has been observed for CD106 and CD166 expression in MSC from pediatric and adult donors. However, this finding is viewed controversially [4] and needs further clarification. Upregulation of surface molecules like VCAM-1 (CD106) or ALCAM (CD166) may have important impact on factors like migration and cell adhesion.
Impact of Isolation Procedure
It is not clear to what extend the surface marker expression is affected by the method used for isolation of MSC. Manipulating MSC might result in up-or down-regulation of markers. It is not proven that the marker used for selection is expressed on all differentiation stages. There is a risk that the markers used for isolation are not expressed in immature progenitor cells which therefore are lost during the selection procedure. The resulting MSC preparation might have a reduced capacity in differentiation, migration, immune modulation, or surface marker expression.
Impact of in vitro Senescence
Senescence may play an important role during expansion of MSC for clinical purposes. Mareddy et al. [5] demonstrated recently that slow growing MSC clones may show senescence and reduced differentiation capacity but still express normal levels of standard MSC surface markers like CD29, CD44, CD90, CD105, and CD166. As demonstrated in figure 2 , expression of markers might be down-regulated during expansion and aging, due to cell contact, plastic adherence, contact with (non-human) growth factors, or enzymatic manipulation (e.g. trypsin). This fact may also explain the differences in expression profiles described for adhesion molecules and chemokines. As described above, CD271 expression was de- depleted BM-preparations -significantly less (about 30 and 50%) CFU-F colonies for CD271 depleted preparations from CM and AM, respectively -rotation of cells and beads during incubation -non-attached cells were removed after 48 h and beads were washed -isolated cells were negative for CD45 and CD34 -isolated cells were positive for CD90 and CD105, vimentin and fibronectin -isolated cells could be differentiated into adipocytes, chondrocytes, and osteoblasts Table 3 continued on next page tectable in different amounts in freshly isolated preparations from BM, chorionic, and amniotic membranes but disappeared after culture passages [2] . CD45 was reported to be present on 15% of BM-derived MSC preparations of older patients at passage 1 but decreased to 0.5% at passage 10 [3] .
Impact of Expansion Conditions
MSC phenotype might be influenced by the culture conditions for ex vivo expansion, e.g. type of supplements (fetal bovine serum, human serum, platelet lysate). For standard positive markers like CD73, CD90, CD105, CD106, CD146, and HLA-A,B,C or standard negative markers like CD34, CD45, and HLA-DR no difference could be observed so far [6, 7] . The impact of different culture media (e.g. α-MEM, DMEM, IMDM, Optimem) and medium supplements (e.g. bFGF, heparin, additional amino acids, low or high glucose, addition of deoxyribonucleotides) has never been analyzed in detail. The influence of media mainly may influence proliferation potency, but also lead to marker expression variations of CD44, STRO-1, and HLA-DR [8] and changes in differentiation potency [9] . However, the choice of initial plating densities and plastic source for first step adhesion and expansion mainly plays a role for expansion capacity [7] [8] [9] [10] . In a recent report, Kaiser et al. [11] describe the isolation of MSC from BM by expanding fractions of CD45-/CD34-and CD45+/CD34+ cells. Using fluorescence-activated cell sorting (FACS), they obtained a CD34+ population with only 86% purity, and only 21.8% of cells grew out. Therefore, it cannot be excluded that mainly contaminating CD34-cells were analyzed. After in vitro culture, the phenotype of all isolated fractions changed into CD45-/CD34-. The majority of in vivo MSC in human BM clearly was CD34-/CD45-. These findings contradict reports predicating that most MSC derive from CD49a+/ CD45 med.low cells [12, 13] and turn into CD49a+/CD45-cells when cultured. 
Impact of Detection Methods
The use of different detection methods (flow cytometry, ELISA, micro array, reverse transcription polymerase chain reaction (RT-PCR)) and individual variations within these detection systems like antibody specificity or fluorochrome ( fig. 2 ) may also result in differences in expression profiling.
Isolation or Enrichment of Mesenchymal Stem Cells Based on Surface Marker Expression Patterns
Several attempts have been made for prospective isolation of MSC by selection of MSC-containing subpopulations from various sources (table 3) such as BM, buffy coat, endometrium, placenta, amniotic and chorionic membrane, or granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood. Several cell surface markers listed in tables 1 and 2 were applied for positive or negative selection using magnetic immunobead-based or fluorescence-activated cell sorting. The cell populations isolated by these different methods show the typical MSC characteristic and differentiation capacity as far as tested in the individual attempts. Several of the positive selection markers like CD271, CD34, CD45, and CD133 disappear during ex vivo expansion. Novel attempts like aptamerbased magnetic immunobead-activated cell sorting have not yet been published for human MSC [14, 15] . Table 4 summarizes the origin and immunophenotypic characterization of MSC used in recent clinical trials with MSC. The description of expanded MSC used for patients is either published in detail (surface antigen expression, testing of differentiation capacity), or no statement is given on the characterization of the cells. The expression of CD105 in combination with at least one additional marker was analyzed as the minimum standard in most trials, except those where no information on surface marker was available (table 4) . In several trials, the expression of CD73, CD29, or CD44 and lack of expression of CD34, or CD14 and CD45 were included as criteria for expanded MSC. Despite some overlap, marker panels are rather heterogeneous. Differentiation capacity of ex vivo-expanded MSC was determined in few trials only.
Characterization of Mesenchymal Stem Cells Used for Clinical Trials

The Quandary to Define Surface Markers for Mesenchymal Stem Cells
Characterization of MSC by the establishment of a clearly defined, well deliberated surface marker expression panel might be helpful to define expanded MSC for special purposes. However, characterization of MSC solely by surface antigen expression has to be reconsidered, especially as this characterization may not be helpful to identify MSC precursors or isolate MSC from the original source. Markers like CD133 [16] or CD34 [11] , which generally are requested to be absent on MSC preparations (tables 1 and 2) but are described to be prospective markers, need further investigation (table 3) . The discrepancy of surface antigen expression in unprocessed raw material and expanded MSC preparations used for clinical purpose has to be investigated in more detail.
Minimal Requirements for Mesenchymal Stem Cell Characterizations
All these discrepancies make it difficult to find clear and generally applicable parameters for the definition of MSC. In a first step, there has to be a clear definition on what MSC stands for. MSC has synonymously been used for different types and qualities of cells like mesenchymal stem cells, mesenchymal stromal cells, multipotent stromal cells but also mesenchymal progenitor cells, regardless from which tissue they have been isolated: BM, spongiosa, G-CSF-mobilized peripheral blood, placenta, dental pulp, pancreas, fetal blood, cord blood, adipose tissue, endometrium, or amniotic and chorionic membrane or villi. During the last years, it has become obvious that stem cell-like or progenitor-like populations with MSC features can be isolated from virtually any tissue, not only from mice [17] but most probably also from humans. Therefore, the International Society for Cellular Therapy (ISCT) published a position statement on the nomenclature for MSC claiming that only cells meeting the specific stem cell criteria should be referred to as mesenchymal stem cells, whereas all other fibroblast-like plastic-adherent cell preparations, regardless of the tissue from which they are isolated, should be termed mesenchymal stromal cells [18] . Unfortunately, the abbreviation for both mesenchymal stem cells and mesenchymal stromal cells is defined as MSC. The minimal criteria for multipotent mesenchymal stromal cells have been defined by the Mesenchymal and Tissue Stem Cell Committee of the ISCT [19] . MSC must be plastic-adherent in standard culture conditions, express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR. In addition, MSC must differentiate into osteoblasts, adipocytes, and chondroblasts in vitro. However, these criteria are not fulfilled for all cell preparations referred to as MSC in the literature. Unfortunately, several publications on MSC and even publications on clinical trials with MSC (table 4) were done with MSC characterized by only an incomplete panel of surface markers without testing their differentiation capacity. On the other hand, MSC isolated from e.g. adipose tissue may not fulfill all criteria demanded for differentiation potential. As quality control for ex vivo-expanded MSC, we suggest that the panel of positive markers should cover surface proteins expressed by MSC expanded from every tissue (table 1) . These markers may include CD105, CD73, and CD90. In addition, expanded MSC should at least be tested negative for markers of cells that accidentally may be co-isolated and coexpanded, like CD1a or CD33 for dendritic cells, CD14 or CD33 for monocytes, CD3 or CD45 for resting lymphocytes, and CD34 for hematopoietic stem cells. Moreover, the chondrogenic, osteogenic, and adipogenic differentiation potential of ex vivo-expanded MSC has to be proven. For the clinical application of MSC as suppressor of graft-versus-host disease, the anti-proliferative role of MSC in functional assays like mixed lymphocyte reaction may be more suitable than differentiation assays to prove their suitability. As proposed by Bensidhoum et al. [20] for the marker STRO-1, expression, lack of expression, or variation of expression levels for clearly defined markers may help to further subclassify MSC. This might help to develop a helpful tool for isolation of application-specific expandable progenitor cells for special purposes like immune suppression, enhanced engraftment, bone or cartilage formation, or neuronal repair. Stro-1+ cells may rather be used for gene delivery in tissues while Stro-1-cells may rather be used to support hematopoietic engraftment [20] . In this case, both Stro-1+ and Stro-1-cells show differentiation potency. Therefore, Stro-1 might be one of the many useful markers to further characterize phenotypic and functional subpopulations in the MSC pool, and even Stro-1+ or Stro-1-MSC might rather represent a variety of different cell qualities than a unique stem cell quality. Another novel attempt to overcome the dilemma of characterizing MSC is the exploitation of the minimum requirements of MSC that are necessary for a specific function. Parekkadan et al. [21] used bioreactor-expanded MSC to define factors within the secretome of MSC-derived molecules in order to reverse fulminant hepatic failure in mice.
The Need for New Markers and Methods
All things considered, the known surface proteins described for the characterization of MSC are not sufficient to distinguish between subpopulations and different cell types with different intrinsic qualities of MSC. Search for surface antigens representing the pure, native MSC population within the different basic raw materials remains one of the most challenging topics of MSC research for the future. In addition, easy methods for a robust characterization of expanded MSC that do not loose pluripotency or show chromosomal abnormalities due to culturing artifacts have to be established. Time-consuming assays like in vitro differentiation into osteoblasts, chondrocytes, or adipocytes have to be replaced by faster methods. First attempts into this direction have been proposed and performed recently using proteome and microarray screening tests [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . However, establishing more complex assays to characterize MSC may not achieve broad acceptance as long as the definition of MSC by surface proteins still is easier to handle, delivers faster results, and remains less costs intensive than gene expression arrays or complex proteomics.
